Lipoprotein (a), homocysteine, and hypercoagulable states in young men with premature peripheral atherosclerosis: A prospective, controlled analysis  by Valentine, R. James et al.
Lipoprotein (a), homocysteine, and 
hypercoagulable states in young men with 
premature peripheral atherosclerosis: A
prospective, controlled analysis 
R. James Valentine, MD,  Haro ld  S. Kaplan, MD,  Ralph Green, MB, BCh, MD,  
Donald W. Jacobsen, PhD,  Stuart I. Myers, MD,  and G. Patrick Clagett, MD,  
Dallas, Tex., and Cleveland, Ohio 
Purpose: Elevated lipoprotein (a) (Lp[a]) lipoprotein, total homocysteine, and hyperco- 
agulable states (HCS) have all been implicated as risk factors for premature-onset 
atherosclerosis. This study was performed to determine the prevalence of these 
abnormalities in young men with chronic lower extremity ischemia (peripheral vascular 
disease [PVD]) and to determine their relative strengths as risk factors for premature 
peripheral atherosclerosis. 
Methods: We analyzed 50 young white men (age 45 years or younger at onset of symptoms) 
and compared them with 45 age-matched white male control subjects. 
Results: Atherosclerotic risk factors were similar in both groups. The mean (-+ SEM) Lp(a) 
lipoprotein level was 36 - 6 mg/dl among the study patients, compared with 14 + 2 
mg/dl among control subjects (p = 0.02, Mann-Whitney). Twenty (40%) study patients 
and seven (16%) control subjects had Lp(a) lipoprotein levels of 30 mg/dl or greater 
(atherosclerotic r sk threshold) (p = 0.01, odds ratio = 3.62, confidence interval (CI) 1.4 
to 9.5). Positive HCS panels (antiphospholipid antibodies or deficiencies in antithrombin 
I I I ,  protein C, or protein S) were nearly twice as prevalent in study patients (n = 15, 30%) 
as in controls (n = 8, 18%), but this difference did not achieve statistical significance. The 
mean total plasma homocysteine l vel among the study patients was 15.9 --. 0.9 ~mol/L, 
which was not significantly different from the mean control value of 14.7 -+ 0.7 ~mol/L. 
Lp(a) lipoprotein was related to risk of premature PVD through a linear logistic 
relationship (p = 0.003, odds ratio per each 1 mg/dl Lp(a) change was 1.03, CI 1.0 to 
1.1). Multivariate analysis with stepwise logistic regression selected two variables: Lp(a) 
lipoprotein > 30 mg/dl (p = 0.01, odds ratio = 3.6, CI 1.3 to 9.9) and family history 
(p = 0.07, odds ratio = 2.2, CI 0.9 to 5.3). Tests of interaction demonstrated no effect 
between Lp(a) lipoprotein, HCS, and homocysteine. 
Conclusions: Lp(a) lipoprotein of 30 mg/di or greater is an independent risk factor for 
premature peripheral atherosclerosis in men. None of the other examined variables 
exhibited a significant association with premature PVD. (J VASC SURG 1996;23:53-63.) 
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The premature onset of peripheral atherosclerosis 
(peripheral vascular disease [PVD]) in young adults 
carries a poor prognosis, with a high incidence of 
vascular graft occlusion, amputation, and death.~s It 
is unclear why atheroscterosis occurs so early in life 
and appears to be so progressive among these 
individuals. A number of metabolic ~md coagulation 
abnormalities have been identified in patients with 
premature PVD that may be associated with accel- 
erated development of atherosclerosis. Hypercoagu- 
lable states (HCS), 6 hyperhomocysteinemia, 7's nd 
elevated plasma levels of lipoprotein (a) (Lp[a]) 9a~ 
have all been identified in populations of  patients 
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Table I. Demographics and atherosclerotic risk factors among study subjects 
Study patients Control subjects p Value Odds ratio (95% CI) 
No. 50 45 
Mean age (yrs.) 46 +- 0.5 45 • 0.5 0.19" 
History of smoking 49 (98%) 42 (93%) 0.12 
Hypertension 26 (52%) 17 (38%) 0.22 
Dyslipidemia 18 (36%) 9 (20%) 0.12 
Diabetes 11 (22%) 5 (11%) 0.18 
Family history 34 (68%) 22 (49%) 0.07 
CAD 30 (60%) - - 
Cerebrovascular symptoms 6 ( 12% ) - - 
Mean ABI 0.53 +- 0.02 1.06 -+ 0.01 - 
1.1 (i.0, 1.2) 
4.8 (0.6, 37.2) 
1.8 (0.8, 4.1) 
2.3 (0.9, 5.7) 
2.3 (0.7, 7.0) 
2.2 (1.0, 5.1) 
~Logistic regression. 
CI, Confidence interval. 
Table II. Results of laboratory analyses 
Study patients Control subjects p Value Odds ratio (95% CI) 
Lp(a) lipoprotein, mg/dl 35.9 -+ 5.8 13.9 -+ 2.2 0.003* 
No. with Lp(a) lipoprotein 20 (40%) 7 (16%) 0.012 
-> 30 mg/dl 
Homocysteine, ~mol/L 15.9 -+ 0.9 14.7 +- 0.7 0.28* 
No. with homocysteine 29 (58%) 27 (60%) 1.00 
> 13.37 p.mol/L 
No. with identified HCSt 15 (30%) 8 (18%) 0.23 
Antiphospholipid 13 6 0.20 
antibody 
Protein C deficiency 2 2 
Protein S deficiency - - 
Antithrombin III 1 1 
deficiency 
1.03 (1.0, 1.1) change per 1 mg/dl 
3,6 (1.4, 9.4) 
1,0 (1.0, 1.1) 
0.9 (0.4, 2.1) 
2.0 (0.8, 5.2) 
*Logistic regression. 
tOne subject in each group had two identified hypercoagulable states. 
with premature atherosclerosis. However, the rela- 
tive strength of each as a risk factor for premature 
PVD has not been determined. The purposes of this 
study were to determine the prevalence of HCS, 
homocysteinemia, and elevated Lp(a) lipoprotein 
levels in a group of rigorously screened patients with 
premature PVD and to compare them with age- 
matched control subjects to determine the relative 
strength of each abnormality as a risk factor for 
premature PVD. 
METHODS 
Subjects. We studied 50 consecutive white men 
admitted to the vascular surgery service between July 
1992 and September 1994 with symptoms of lower 
extremity atherosclerotic o clusive disease beginning 
at age 45 years or younger. Seven of the patients had 
participated in our previous tudy, 9 but all of them 
underwent complete reevaluation according to the 
present protocol. Patients receiving warfarin were 
excluded from the study. Because Lp(a) is an 
acute-phase r actant, we did not include any subject 
who had had a myocardial infarction, stroke, or 
operation within the previous 6 weeks. All study 
subjects were carefully screened to exclude open 
wounds, rest pain, or gangrene at the time of entry 
into the study. Some patients with these problems 
had phlebotomies deferred until 6 weeks after 
revascularization r amputation, when all wounds 
were healed. Because there is a wide variation in 
Lp(a) lipoprotein levels among racial subgroups 
without a corresponding increase in risk of coronary 
artery disease (CAD), H we excluded black, Asian, 
and Hispanic patients from the analysis. 
For control subjects we studied 45 age-matched 
white men who were selected at random. Many 
control subjects were employees of the Dallas Vet- 
erans Affairs Medical Center, and others were re- 
cruited from outpatient clinics. Control subjects were 
in general good health. Many had atherosclerotic r sk 
factors, but none had symptoms of PVD, CAD, or 
cerebrovascular disease. 
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All study subjects gave informed consent accord- 
ing to a protocol that was approved by the Institu- 
tional Review Board of the medical center. 
Analysis of vascular occlusive disease. After 
demographic data were recorded, each study partici- 
pant was evaluated for the presence of atherosclerotic 
risk factors (history of smoking, hypertension, hy- 
perlipidemia, diabetes mellitus, family history of 
atherosclerosis). Hyperlipidemia was defined as se- 
rum cholesterol f 240 mg/dl or greater or serum 
triglyccrides of 300 mg/dl or greater. Subjects were 
considered tohave a family history of atherosclerosis 
if they had a first-degree r lative with PVD or CAD. 
Detailed histories were obtained regarding the pres- 
ence of CAD (angina, previous myocardial infarc- 
tion, previous coronary artery catheterization, previ- 
ous coronary artery revascularization) and cere- 
brovascular disease (transient ischemic attacks, 
stroke, previous carotid endarterectomy). Patients 
without CAD indicators underwent exercise tread- 
mill tests or adenosine thallium tests. 
All study participants underwent complete valu- 
ation with standard noninvasive t sts. Carotid arter- 
ies were examined with color Doppler imaging and 
spectral analysis (ACUSON 128XP Sonography 
System; Acuson Corp., Mountain View, Calif.). 
Carotid artery stenoses were determined from mea- 
surements of peak systolic velocity, spectral broad- 
ening, and diastolic velocity according to standard- 
ized criteriaJ 2The lower extremity circulation was 
assessed by documenting the presence of pulses. 
Ankle/brachial indexes (ABI) were determined by 
means of a 5.3 MHz Doppler probe (Medasonics, 
Mountain View, Calif.). Toe pressures (TP) were 
determined by plethysmography (Medasonics Meda- 
cord). ABI less than 0.90 and toe pressures less than 
100 mm Hg were considered to indicate flow- 
limiting stenoses involving the circulation of the 
affected leg. ABI and TP were determined in both 
extremities, and the lower values were recorded. 
Laboratory analyses. Thirty milliliters of blood 
was collected after a 14-hour fast by venipuncture. 
Plasma collected in specimen tubes containing eth- 
ylenediamine t traacetic a id was separated immedi- 
ately after collection and frozen in i ml aliquot ubes 
at -70  ~ C. Plasma collected in plain tubes and in 
tubes containing 0.129 mol/L sodium citrate was 
sent fresh to the Coagulation Laboratory at Parkland 
Memorial Hospital, Dallas, Texas, for analysis. 
Plasma Lp(a) concentration was measured in the 
Northwest Lipid Research Laboratory at the Uni- 
versity of Washington, Seattle, (Dr. S. M. Marcovina, 
Director) with a double monoclonal ntibody-based 
enzyme immunoassay performed as recently re- 
portedJ 3 The capture monoclonal antibody (a-6) is 
directed to an epitope present in apo(a) kringle 4 type 
2, and monoclonal ntibody a-40, used for detection, 
is specific to a part ofapo(a) molecule independent of 
the apo(a) size polymorphism. The assay has been 
extensively evaluated, and it has been demonstrated 
that it provides accurate Lp(a) measurements inde- 
pendent of the apo(a) size heterogeneity, s Even 
though this assay has the potential to express the 
results in nmol/L, it was elected to express the Lp(a) 
values in terms of total Lp(a) mass (lipid, protein, 
carbohydrate) to compare the present values to those 
published in the literature. Among white patients, 
Lp(a) lipoprotein of 30 mg/dl or greater has been 
established asa risk threshold for the development of 
cardiovascular disease.14 
Total plasma homocysteine levels were measured 
at the Research Institute of the Cleveland Clinic 
Foundation by use of high-performance liquid chro- 
matography aspreviously reported.XS Briefly, plasma 
samples (100 I~1) were simultaneously reduced with 
sodium borohydride and derivatized with mono- 
bromobimane. Homocysteine-S-bimane was re- 
solved from other low-molecular weight thiol- 
bimanes by automated high-performance liquid 
chromatography and detected fluorometrically. In
this method both free and oxidized forms (ho- 
mocystine, homocysteine-cysteine mixed disulfide, 
and protein-bound homocysteine) of homocysteine 
are determined. Plasma homocysteine levels exceed- 
ing 13.37 ~mol/L were considered to be elevated; 
this value was previously established astwo standard 
deviations above the mean plasma homocysteine 
level for men at the Cleveland Clinic. is 
Coagulation assays were performed in the Co- 
agulation Laboratory of Parkland Memorial Hospi- 
tal. Results were compared with a local normal range 
and were treated as a dichotomous variable. HCS 
panels included measurement of antithrombin III, 
protein C, protein S, and antiphosphofipid antibod- 
ies. Antithrombin III activity was measured by use of 
a chromogenic substrate with the COAMATIC 
Antithrombin Kit (Chromogenix AB, Molndal, Swe- 
den). Quantitative determination f protein C func- 
tion on the basis of the prolongation of the activated 
partial thromboplastin time was measured by use of 
STACLOT Protein C Kit (Diagnostica Stago, 
Ansieres-Sur-Seine, France). Quantitative determi- 
nation of protein S function on the basis of the 
inhibition of factor Va was measured by use of 
STACLOT Protein S Kit (Diagnostica Stago). The 
presence of antiphospholipid antibodies (lupus anti- 
JOURNAL OF VASCULAR SURGERY 
56  Valentine et al. January 1996 
coagulant, anticardiolipins) was determined by the 
use of functional clotting assays (lupus anticoagulant) 
or immunologic assays (anticardiolipin antibodies). 
Three different tests were carried out to determine 
the presence of lupus anticoagulant. These included 
dilute Russell's Viper Venom Time (DVVtest; 
American Diagnostica, Greenwich, Conn.), hexa- 
gonal (II) phase phospholipid neutralization 
(STACLOT LA, Diagnostica Stago), and the platelet 
neutralization procedure with platelet-derived phos- 
pholipid used as described by Triplett et al. 16 
Anticardiolipin antibodies were detected by in- 
direct enzyme-linked immunosorbent assay with 
READS Anti-Cardiolipin Semi-quantitative Test Kit 
(READS Medical Products, Inc., Westminster, 
Colo.). Levels of immunoglobulin G, immunoglob- 
ulin M, and immunoglobulin A anticardiolipin 
antibodies were measured and compared with a 
control reference range. 
Statistical analysis. Continuous data are ex- 
pressed as mean _+ SEM. For univariate comparisons 
of risk factors with the study groups, Fisher's exact 
test was used for the categorical risk factors, and the 
Mann-Whitney U test was used for continuous 
measures. Logistic regression was used to provide 
p values and odds ratios for the continuous measures, 
considering the study group as the outcome measure. 
Stepwise logistic regression was provided for variable 
selection of the risk factors for association with the 
study group. Significance for entry into the logistical 
model was set conservatively at 0.10 to allow more 
factors into the model. To examine possible interac- 
tions between Lp(a) lipoprotein, HCS, and ho- 
mocysteine, the Breslow-Day statistic was used to test 
the null hypothesis of equal odds ratios across trata 
(Lp[a], HCS, homocysteine) or the interaction of 
HCS and homocysteine in patients with Lp(a) 
lipoprotein less than 30 mg/dl. 
RESULTS 
Study patients. The mean age of the 50 patients 
at entry into the study was 46 + 0.5 years, and the 
mean age at onset of symptoms was 41 + 0.6 years. 
Twenty-six (52%) of the patients were older than 45 
years at the time of entry into the study, but all had 
PVD symptoms beginning at age 45 years or 
younger. Demographics and atherosclerotic r sk fac- 
tors of the study subjects are demonstrated in Table 
I. AUS0 study patients were admitted with intermit- 
tent claudication of at least 1 year's duration. 
Seventeen patients (34%) progressed to have rest 
pain, and four of these (8%) had evidence of tissue 
loss. The mean ABI among the 50 study patients was 
0.53 + 0.02, and the mean TP was 56 +_ 5 mm Hg. 
Thirty (60%) of the study patients had CAD. 
This diagnosis was made by a history of coronary 
artery revascularization in 14, by coronary catheter- 
ization in 13, by electrocardiography (Q waves) in 2, 
and by dipyridamole thallium scanning (fixed reper- 
fusion defect) in 1. Twenty (40%) study patients had 
CAD excluded by exercise treadmill testing in 14, by 
coronary catheterization in 3, and by adenosine thal- 
lium scanning in 3. 
Six (12%) study patients had a history of cere- 
brovascular symptoms (two transient ischemic at- 
tacks, four strokes), and two of these patients had 
undergone previous carotid endarterectomies. 
Twenty-one (42%) had evidence of carotid artery 
stenoses by duplex scanning: stenoses measured 1% 
to 49% in nine, 50% to 79% in six, and 80% to 99% 
in two. Four patients had internal carotid artery 
occlusions. 
Controls. Among the 45 control subjects, PVD 
was excluded on the basis of noninvasive t st results 
and absence of symptoms. The mean ABI among the 
control subjects was 1.06 + 0.01 (Table I). None of 
the control subjects had symptoms or electrocardio- 
graphic evidence of CAD. Thirty-nine (87%) of the 
control subjects had CAD excluded by exercise 
treadmill testing, two had normal exercise thallium 
scan results, and four had normal coronary catheter- 
ization results. The mean age of the control subjects 
was not different han the mean age of the study 
patients, and there were no differences in atheroscle- 
rotic risk factors between the two groups (Table I). 
Laboratory analyses. The mean Lp(a) lipopro- 
tein level among the 50 study patients was 
35.9 + 5.8 mg/dl, which was significantly higher 
than the control mean of 13.9 +__ 2.2 mg/dl 
(p = 0.02, Mann-Whitney). Twenty (40%) of the 
study patients had an Lp(a) lipoprotein of 30 mg/dl 
or greater, as did seven (16%) of the control subjects 
(p = 0.01, odds ratio = 3.6, CI 1:4 to 9.5) (Table 
II). One of the seven control subjects with Lp(a) 
lipoprotein of 30 mg/dl or greater also had an 
elevated homocysteine level, and one other had an 
antiphospholipid antibody. There was no difference 
in type or number of atherosclerotic r sk factors in 
study subjects with Lp(a) lipoprotein of 30 mg]dl or 
greater versus control subjects with Lp(a) lipoprotein 
of 30 mg/dl or greater. Compared with study patients 
with Lp(a) lipoprotein less than 30 mg/dl, subjects 
with Lp(a) lipoprotein of 30 mg/dl or greater had a 
similar mean age of onset (42 years vs 40 years), mean 
API (0.52 vs 0.55), prevalence of CAD (53% vs 
70%), prevalence of carotid artery disease (20% vs 
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Fig. 1. Negative cumulative Lp(a) distribution of two study groups. Each point represents 
percent (_+ SEM) of study patients and control subjects who had Lp(a) lipoprotein levels 
exceeding given value on x-axis. 
30%), and proportion admitted with limb- 
threatening ischemia (30% vs 40%). Lp(a) lipo- 
protein was related to risk of premature PVD 
through a linear logistic relationship (p -- 0.003, 
odds ratio per 1 mg/dl Lp(a) change = 1.03, CI 
1.0 to 1.1). Fig. 1 demonstrates the negative 
cumulative Lp(a) lipoprotein distributions of the 
two study groups. 
The mean plasma homocysteine level among the 
study patients was 15.9 -+ 0.9 ~mol/L, which was 
not significantly different compared with the mean 
control value of 14.7 + 0.7 i~mol/L. Twenty-nine 
(58%) of the study patients and 27 (60%) of the 
control subjects had plasma homocysteine l vels 
greater than 13.37 ixmol/L. 
Fifteen (30%) of the study patients had a defined 
HCS, which was not significantly more than eight 
(18%) of the control subjects. Thirteen (26%) study 
patients had antiphospholipid antibodies (two had 
lupus anticoagulant, 11 had anticardiolipin anti- 
body), as did six (13%) of the control subjects (all 
anticardiolipin antibody) (p -- 0.20). Although this 
difference did not achieve statistical significance, the 
effect size of the 13% difference had an observed 
power of 0.34. 
Stepwise logistic regression analysis elected two 
variables: Lp(a) lipoprotein and family history. 
Lp(a) !ipoprotein was selected in the model with 
Lp(a) of 30 mg/dl or greater (p = 0.01, odds ratio 
3.6, CI 1.3 to 9.9) and in the model with Lp(a) 
lipoprotein used as a continuous measure 
(p = 0.003, odds ratio per 1 mg/dl change 1.03, 
CI 1.0 to 1.1). In both models, family history did 
not achieve statistical significance (p -- 0.07, odds 
ratio 2.2, CI 0.9 to 5.3). The ratios as expressed 
by univariate analyses were similar in the multi- 
variate model, demonstrating a lack of synergism 
among these variables. 
The Breslow-Day statistic did not demonstrate an
interactive ffect between Lp(a) lipoprotein and 
homocysteine; Lp(a) lipoprotein and HCS; or a 
combination of Lp(a) lipoprotein, homocysteine, 
and HCS. The odds ratios were not significantly 
different across the strata. There were no interactive 
effects of HCS or homocysteine demonstrated in 
patients with Lp(a) less than 30 mg/dl. 
DISCUSSION 
The early onset of symptoms in young adults is 
generally assumed to represent an acceleration fthe 
atherosclerotic process, which begins in late child- 
hood. 17,~s Several blood and coagulation abnormali- 
ties have been proposed as causes of accelerated 
atherosclerosis, including HCS, hyperhomocysteine- 
mia, and elevated plasma levels of Lp(a) lipoprotein. 
Previous studies have demonstrated that HCS are 
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Fig. 2. Schematic omparisons of LDL and Lp(a) lipoprotein. Both structures contain 
apoprotein B-100 molecule. Lp(a) lipoprotein is distinguished by addition of apoprotein (a) 
moiety, which is attached to apoprotein B-100 by disulfide bond. (From: Valentine RJ. 
Lipoprotein (a): A new risk factor for vascular disease. Perspect Vasc Surg 1992;5:84-99. 
Reproduced with permission.) 
prevalent among patients with premature atheroscle- 
rosis affecting the peripheral 6 and coronary 19 circu- 
lations. Antiphospholipid antibodies are considered 
to be the most common of the HCS causing arterial 
thrombosis, 2~ and this was also borne out in this 
study. Although the difference in prevalence of 
antiphospholipid antibodies between our study pa- 
tients and control subjects did not achieve statistical 
significance, the risk of a type II statistical error must 
be acknowledged. The likelihood of statistical sig- 
nificance with the effect size of a 13% difference was 
only 0.34. It is likely that the observed twofold higher 
prevalence of antiphospholipid antibody in the study 
group represents an important rend and that a 
significant difference would be observed among a 
larger study population. 
Mild to moderate levations of plasma homocys- 
teine, a metabolite of methionine metabolism, have 
also been associated with atherosclerosis n the 
coronary and peripheral arteries. 7`s'2~2a The mecha- 
nism of homocysteine-induced atherosclerosis ap- 
pears to be related to impairment of endothelial cell 
thromboresistance and the stimulation of procoagu- 
lant activities by homocysteine. 21 We were unable to 
demonstrate an association between plasma ho- 
mocysteine l vels and premature PVD. The mean 
plasma homocysteine level among our study patients 
was similar to the mean levels previously reported 
among men with PVD. 2L24 Although the mean 
plasma homocysteine l vel of our control subjects 
was higher than that previously reported, it should be 
emphasized that the homocysteine levels of our study 
patients were compared with those of control sub- 
jects matched for age, sex, race, and risk factors who 
had no evidence of atherosclerosis on the basis of 
objective test results. The mean control value was in 
keeping with those previously reported for young 
men. 2s,2s However, this mean value appears to be 
somewhat higher, for reasons not completely under- 
stood, than anticipated on the basis of recent study 
results.~S 
Elevated plasma Lp(a) lipoprotein has been 
associated with premature CAD, 26 premature cere- 
brovascular disease, 27 and premature PVD. 9 Lp(a) 
lipoprotein is structurally similar to low density 
lipoprotein (LDL) but is distinguished by the 
addition of apoprotein (a) (Fig. 2). The two most 
popular theories used to explain the association 
between elevated Lp(a) levels and premature or 
accelerated atherosclerosis are the plasminogen in- 
hibitor theory 27 and the cholesterol targeting 
theory. 28 The plasminogen i hibitor theory is based 
on the fact that apoprotein (a) is structurally homolo- 
gous to plasminogen. Lp(a) lipoprotein isbelieved to 
exert an inhibitory influence on the fibrinotytic 
system by competitively inhibiting the binding of 
plasminogen to endothelial cells, which leads to 
prolonged intimal damage from the effects of local 
thrombus formation. According to the cholesterol 
targeting theory, Lp(a) has an important physiologic 
role on the basis of its LDL moiety. By binding to 
plasminogen receptors at sites of endothelial injury, 
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Lp(a) targets delivery of cholesterol where it is 
needed, in an area of rapid cell growth. Abnormally 
high plasma levels of Lp(a) lipoprotein lead to an 
excess of cholesterol deposition at vessel wall injury 
sites, predisposing to formation of plaque. Plasma 
Lp(a) levels are under the strict control of a single 
gene locus. An individual's Lp(a) level is constant 
over long periods of time29; therefore if Lp(a) 
lipoprotein has potential as a risk factor for premature 
atherosclerosis, a single plasma determination could 
be used for risk stratification. It should be pointed out 
that Lp(a) distributions vary among selected popu- 
lations, and that mean Lp(a) levels are race-specific. 
For example, mean Lp(a) levels among population 
subsamples ofAmerican black men and women have 
been found to be twice as high as mean levels of 
American white men and women, s~ Despite this 
difference in Lp(a) distributions, the incidence of 
coronary atherosclerosis is not different between the 
two groups. The reason for this race-dependent 
variability in Lp(a) levels is believed to be related to 
differences in expression of apoprotein (a) molecular 
size. This race dependency underlies our decision to 
confine our study to white subjects. 
Our data demonstrate that elevated levels of 
Lp(a) lipoprotein have the strongest association with 
premature PVD among the examined variables. We 
have previously shown that elevated Lp(a) lipopro- 
rein levels have the strongest association with pre- 
mature PVD among standard lipid variables (total 
cholesterol, triglycerides, LDL, high density lipopro- 
rein, and apoproteins A 1 and B100). 9 These data 
further strengthen the evidence that Lp(a) lipopro- 
tein is an important risk factor for premature PVD. 
By logistic regression, the Lp(a) risk appears to be 
linear; that is, each 1 mg/dl rise in plasma Lp(a) 
lipoprotein is associated with an odds ratio of 1.03. 
For example, an individual with an Lp(a) lipoprotein 
level of 30 rng/dl is 2.03 times as likely to have 
premature PVD compared with an individual with an 
Lp(a) lipoprotein level of 5 mg/dl. This is in keeping 
with published population studies, which suggest 
that white patients with plasma Lp(a) lipoprotein 
concentrations of 30 mg/dl or greater have a two to 
three times greater isk for development of cardio- 
vascular disease. ~4 
Despite the fact that this was a prospective and 
controlled study, limitations did exist. One potential 
limitation is that the nature of our referral population 
restricted the focus of our study to men. Although 
our findings do not apply to women, at least one 
previous tudy has linked elevated Lp(a) levels to the 
development of premature PVD in women, 3~ and 
several have demonstrated an independent associa- 
tion between Lp(a) and senescent PVD in both men 
and women. 32,3s By extrapolation, we speculate that 
elevated Lp(a) lipoprotein is an equally significant 
risk factor for premature PVD among women and 
men.  
Another potential limitation is that we did not 
include an older group of patients with atheroscle- 
rosis to compare with patients who had premature- 
onset atherosclerosis. Thus we are unable to say that 
elevated Lp(a) levels are a particular marker for 
premature atherosclerosis. It is possible that elevated 
Lp(a) is a marker for atherosclerosis, regardless of the 
age of onset. Nevertheless, the findings of this study 
demonstrate hat Lp(a) lipoprotein is an important 
risk factor for atherosclerosis in young patients. The 
association is stronger than that of HCS or hyper- 
homocysteinemia. 
Another potential limitation of this study is that 
study subjects were not screened for all possible 
known hypercoagulable conditions. Several HCS 
that have been associated with venous or arterial 
thromboembolic complications, but not with accel- 
erated or premature atherosclerosis, were not in- 
cluded in this analysis. These include activated 
protein C resistance; elevations of fibrinogen, von 
Willebrand factor antigen, tissue plasminogen acti- 
vator antigen, and C-reactive protein; and deficien- 
cies in heparin cofactor II and plasminogen activator 
inhibitor. Two other abnormalities, plasminogen 
deficiency and increased platelet aggregation, have 
been linked to premature PVD. Eldrup-Jorgensen t
al. 6 reported a 10% prevalence of plasminogen 
deficiency and a 47% prevalence of increased platelet 
aggregation among a small group of patients with 
premature PVD who were prospectively screened. 
We initially evaluated plasminogen levels and per- 
formed platelet aggregation studies in our study 
subjects but discontinued the assays because no 
abnormalities were found among the first 40 study 
patients and 15 control subjects creened. 
Another potential criticism of our method is that 
methionine loading was not used in the evaluation of 
homocysteine metabolism. However, the develop- 
ment of sensitive assays by use of high-performance 
liquid chromatography ave led to accurate determi- 
nations of basal total homocysteine leve~s without he 
need for methionine loading. Taylor and Porter s4 
have demonstrated that patients with elevated basal 
levels of homocysteine uniformly had markedly 
elevated levels after methionine loading, with the 
resultant increase proportional to basal evels. Thus 
methionine loading does not increase the sensitivity 
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of basal levels in detecting abnormal homocysteine 
metabolism. 
Although these data demonstrate the high asso- 
ciation between Lp(a) lipoprotein and premature 
PVD, many issues remain unresolved. First, not all 
patients in the study group had an elevated Lp(a) 
lipoprotein value. Among the 30 (60%) patients with 
Lp(a) less than 30 mg/dl, neither HCS nor homocys- 
teine demonstrated a significant contributing effect. 
Thus we were unable to identify independent risk 
factors for premature atherosclerosis n most of the 
study patients. It is likely that additional risk factors 
will be identified in the future. We are currently 
evaluating the influence of inheritance on the devel- 
opment of premature PVD. 
A second unresolved issue concerns recommen- 
dations for patients with premature PVD who have 
elevated Lp(a). There are no currently known reliable 
methods of reducing Lp(a) lipoprotein levels. Fur- 
thermore, it is uncertain whether Lp(a) is the direct 
cause of the accelerated atherosclerosis or a marker 
for other metabolic abnormalities. It has not been 
determined whether young patients with elevated 
Lp(a) levels continue to have accelerated atheroscle- 
rosis after the development of premature PVD. 
Further prospective studies will be required to 
determine long-term morbidity and mortality rates 
among patients with normal versus elevated Lp(a) 
levels. At this time, we regard Lp(a) as a strong risk 
factor for premature PVD. 
Although the importance of reducing an elevated 
Lp(a) lipoprotein level remains uncertain, these data 
suggest hat homocysteinemia s of dubious signifi- 
cance in the development of premature PVD among 
men. Thus premature PVD is not an indication as 
such for determination of homocysteine levels in 
men. The role of antiphospholipid antibody in the 
development of PVD is uncertain, but it may play at 
least some part in the development of premature 
atherosclerosis separate from Lp(a) lipoprotein. We 
recommend screening for antiphospholipid antibody 
in these patients. Although control of recurrent 
arterial thrombotic episodes in patients with an- 
tiphospholipid antibody is difficult, long-term anti- 
coagulation with warfarin to maintain the interna- 
tional normalized ratio above three has been shown 
to reduce recurrent events. 3s Determination of Lp (a) 
lipoprotein levels may prove useful as one part of a 
battery of tests to determine the risk of premature 
atherosclerosis, and it can be used in future studies 
determining the relative strengths of new risk factors. 
We continue to recommend careful control of 
reversible atherosclerotic risk factors in these patients, 
especially cessation of smoking. In addition, the 
predisposition for progression of disease in these 
patients represents a strong indication for close 
clinical follow-up and appropriate intervention to 
prevent limb loss and death. 
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DISCUSSION 
Dr. Lloyd M. Taylor, Jr. (Portland, Ore.). The 
authors' tated purpose was to "determine the prevalence of
hypercoagulable states, homocystinemia, nd elevated 
Lp(a) in a group of patients with premature PVD and to 
compare them to age-matched control subjects to deter- 
mine the relative strength of each abnormality as a risk 
factor for premature peripheral vascular disease." They 
studied 50 consecutive white male patients and 45 control 
subjects who were matched for age, race, and sex and who 
were free of clinical symptoms. Most had noninvasive 
testing that confirmed the absence of disease. The statistical 
method was appropriate, but it must be interpreted with 
some caution in a study with small numbers of patients and 
control subjects. 
The authors' findings were that elevated levels of Lp(a) 
and family history were the only two risk fhctors signifi- 
cantly more prevalent among the patients as compared with 
control subjects. Although elevated plasma homocysteine 
levels and the presence ofhypercoagulable states were more 
frequent in patients, the differences were too small to be 
significant in this study. Because both of these parameters 
have been documented asrisk factors for atherosclerosis in 
multiple previous studies, we must address why the 
findings of this study are different. I believe that the 
explanation can be found in some basic flaws in the authors' 
study design. 
The first problem has to do with the description of this 
study as a controlled study of premature atherosclerosis. 
The patients all fit the definition of premature disease, and 
the control subjects were age matched. Unfortunately, an 
important control group was not included; namely, pa-" 
tients with atherosclerotic PVD with onset of symptoms 
alter age 45 years. As the authors are well aware, each of the 
risk factors they examined has been identified as associated 
with atherosclerotic disease regardless of patient age. 
Nothing in this study allows us to conclude that the 
findings are peculiar to patients with premature onset of 
disease. The necessary controls are simply not there. I 
hasten to point out that this same defect is present in most 
existing studies of premature atherosclerosis. 
The second problem has to do with sample size. Risk 
factor esearch regarding atherosclerosis, a disease affecting 
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literally millions of subjects, is difficult in small groups. 
Drawing conclusions from this study of 50 patients with 
atherosclerosis is alittle like trying to guess the nature of the 
Mississippi River from a single glass of water. As the 
authors correctly point out in their manuscript, he study 
has little power to allow negative conclusions. The 
possibility of a type II error is significant indeed. 
Finally, I 'm concerned about the control population. 
Ninety-three percent had a history of smoking, and 38% 
had hypertension; diabetes and hyperlipidemia were com- 
mon. Although they clearly did not have premature 
symptomatic atherosclerosis, I uspect they were not too far 
from development ofpostmature disease. This may explain 
why the mean level of plasma homocysteine in the control 
subjects was not different from that found in the patients 
but was considerably higher than that reported by most 
other studies in the literature. 
Do you really believe that premature atherosclerosis has 
risk factors any different from atherosclerosis with onset of 
symptoms later in life? Certainly the factors you examined 
have been well documented as relevant to atherosclerotic 
disease regardless of age. 
How certain are you that your control population was 
truly free of disease? The prevalence of smoking alone was 
sufficiently high to question this finding. 
Do you plan to add a control group with later onset of 
symptoms? Without these it does not seem permissible to 
me to characterize your study as being one of premature 
atherosclerosis. 
Dr. R. James Valentine. Regarding our sample size of 
50 patients, we certainly agree that it would be desirable in 
an epidemiologic study of this type to examine several 
thousand subjects to determine the true incidence of the 
study variables. Unfbrtunately, premature atherosclerosis is 
sufficiently rare that the usual epidemiologic tools cannot 
be applied. It is for this reason that we chose to develop a
control group of young adults with similar risk factors but 
who did not have atherosclerosis to compare the variables 
ofLp(a), homocysteine, and hypercoagulable state. We did 
not examine an older control group with atherosclerosis. 
Comparing the young patients with atherosclerosis to an 
older group of patients with atherosclerosis would be 
tantamount to examining the effect of age on the variables 
that we had in our study, and it was our intention to 
examine the effect of these variables on atherosclerosis. 
Your first question regarded whether we really believe 
that premature atherosclerosis is any different from ath- 
erosclerosis with later onset. Yes. Atherosclerosis a 
process that begins in late childhood, and the premature 
appearance of symptomatic arterial occlusive disease is 
generally regarded as an acceleration of the atherosclerotic 
process. We have hypothesized that there must be some- 
thing fundamentally different in young patients to get the 
acceleration u derway. Our data demonstrate hat elevated 
Lp(a) has a strong association with premature atheroscle- 
rosis, and this association is stronger than that with 
homocysteine or hypercoagulable states. Although a cause- 
and-effect relationship has not been established, we regard 
an elevated Lp(a) level as a strong risk factor for premature 
atherosclerosis. 
Your second question was how certain were we that 
our control population was truly free of disease, given the 
fact that they had a high prevalence of risk factors. We spent 
a great deal of time ruling out occlusive disease in our 
control population. None of the controls had symptoms of 
occlusive disease. On carotid artery duplex scanning, there 
was no evidence of wall thickening or luminal irregularities. 
All of the controls had palpable pedal pulses, normal ABIs, 
and normal TP. We used standard noninvasive t sts to rule 
out the presence of CAD; in some cases we even performed 
coronary catheterization. Sowe are as certain as we can be 
without routine arteriography and routine coronary cath- 
eterization that these individuals did not have vascular 
disease. Are the control subjects going to have development 
ofatherosclerosis? Probably. However, because atheroscle- 
rosis will not appear in any of the control subjects not 
before the age of 45, I believe that it is proper to use these 
individuals as a control group that does not have premature 
atherosclerosis. 
Your third question regarded adding a secondary 
control group with a later onset of symptoms. Again, 
comparing Lp(a), homocysteine, and hypercoagulable 
states in young patients with atherosclerosis versus older 
patients with atherosclerosis really is comparing the effect 
of age on the variables that we examined. Although this is 
interesting, I believe that our basic purpose was to examine 
the effect of the study variables on the presence of 
atherosclerosis rather than age, and therefore our choice of 
control group was probably a more appropriate one. 
Dr. Michael K. Deiparine (Loma Linda, Calif.). 
Given the cost of all the tests to screen for these various 
deficiencies, when do you recommend screening people, 
initially when they are young and have a problem or after 
first failure of a graft? 
Do you treat a person who has a graft put in and has 
thrombosis when screening results are negative? 
What is the cost of all these panels and how does it 
relate to the cost per diagnosis of a person with a particular 
defect? 
What is the role of screening people outside of a study 
setting? 
Dr. Valentine. On the basis of the data that I 
presented, we recommend selective screening in all patients 
in the community and other settings. Currently, measure- 
ment of Lp(a) levels is largely of experimental interest. 
There are no known methods at this time to reduce an 
elevated Lp(a) level. This is moot because a cause-and- 
effect relationship has not been established between Lp(a) 
and premature atherosclerosis. We currently regard mea- 
suring Lp(a) levels important in terms of prognostic 
implications rather than therapeutic mplications. 
We recommend screening patients with premature 
atherosclerosis for antiphospholipid antibodies. Our data 
demonstrated a strong trend toward a higher prevalence of 
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antiphospholipid antibodies in patients with premature 
atherosclerosis. The antiphospholipid antibody has been 
associated with an increased risk of graft complications. As 
you know, it's very difficult to control thrombotic ompli- 
cations in a patient with an antiphospholipid antibody. 
However, recent data suggest that lifelong anticoagulation 
with warfarin to maintain an international normalized ratio 
of approximately 3 will significantly reduce thrombotic 
complications in these patients. 
You asked a question regarding screening patients who 
have already had development of thrombotic omplica- 
tions. To avoid erroneous results from acute phase 
reactants, I would wait approximately 6 weeks after 
operation and screen them for antiphospholipid antibod- 
ies. Patients without antiphospholipid antibodies hould 
probably be treated the same as any other patient with 
complications of atherosclerosis; I would not recommend 
treating patients without hypercoagulable states with 
lifelong anticoagulation. It is imperative to control other 
known atherosclerotic risk factors in these patients, espe- 
cially smoking. 
Dr. Charles O. Brantigan (Denver, Colo.). You've 
said that if you identify the Lp(a) problem in people, 
nobody knows what to do about it. Let me ask the same 
question about he hyperhomocystinemia, what do you do 
about that? 
Dr. Valentine. I believe we've shown fairly conclu- 
sively from our small study population that there was no 
higher incidence of homocysteine abnormalities in our 
patients with PVD, so we don't recommend screening for 
hyperhomocysteineimia in that patient population. How- 
ever, we would screen young patients with a history of 
hyperhomocysteineimia. It should be pointed out that a 
definite threshold for elevated homocysteine has not been 
established. However, patients with elevated levels should 
also be screened for vitamin B~z and folate deficiencies, 
which are easily treatable. 
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